Anzeige
Mehr »
Donnerstag, 25.09.2025 - Börsentäglich über 12.000 News
Geheime Börsenchance: Ist das die bedeutendste Kupferentdeckung Kanadas?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P200 | ISIN: KYG0146B1032 | Ticker-Symbol: 4RY
Tradegate
24.09.25 | 21:14
14,900 Euro
-0,67 % -0,100
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
AKESO INC Chart 1 Jahr
5-Tage-Chart
AKESO INC 5-Tage-Chart
RealtimeGeldBriefZeit
14,80015,30020:56
14,70015,30020:56

Aktuelle News zur AKESO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiAkeso, Inc.: Ivonescimab HARMONi-6 Results Selected for ESMO 2025 LBA; Final Phase III Results of Cadonilimab as First-Line Therapy for Advanced Gastric Cancer to Be Published as an Oral Presentation82HONG KONG, Sept. 22, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) is excited to announce that the Late-Breaking Abstract (LBA) from the registrational Phase III...
► Artikel lesen
MoAkeso, Inc.: Akeso Announces First Patient Dosed in Registrational Phase II Study of TIGIT/TGF-ß Bifunctional Antibody Fusion Protein AK130 Combined with Ivonescimab for Advanced Pancreatic Cancer63HONG KONG, Sept. 22, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) has announced that the first patient has been dosed in its registrational Phase II study (AK130-202)...
► Artikel lesen
16.09.Akeso's cancer therapy gets orphan status from US FDA4
16.09.Akeso's Ligufalimab Receives FDA Orphan Drug Designation For Acute Myeloid Leukemia-
16.09.Akeso, Inc.: Akeso's Ligufalimab (CD47 mAb) Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia (AML)100HONG KONG, Sept. 15, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) today announced that its proprietary next-generation humanized IgG4 monoclonal antibody targeting...
► Artikel lesen
AKESO Aktie jetzt für 0€ handeln
15.09.Akeso, Inc.: Akeso Announces First Patient Dose in Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma72HONG KONG, Sept. 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its global, multicenter...
► Artikel lesen
10.09.Akeso, Inc.: Cadonilimab(PD-1/CTLA-4) plus Pulocimab (VEGFR-2) Combination Therapy Shows Promising Results in IO-Resistant Non-Small Cell Lung Cancer in Oral Presentation at the 2025 WCLC119HONG KONG, Sept. 9, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) announced that data from a Phase Ib/II clinical study evaluating the combination of cadonilimab...
► Artikel lesen
09.09.HSBC Research Mildly Cuts AKESO's TP to HKD205 amid Mkt Concerns Over AK112's Weaker Efficacy in Western Patients6
09.09.AKESO Continues Lower by ~7% in Early Trading; Uncertainty in US Mkt for Lung Cancer Drug9
08.09.AKESO's Stock Price Dented by Doubts in US Mkt Prospects of Lung Cancer Drug12
04.09.AKESO (09926): NEXT DAY DISCLOSURE RETURN2
04.09.AKESO (09926): COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE AND PLACING OF EXISTING SHARES2
04.09.Akeso shares take a hit despite surging sales of cancer drugs2
02.09.Akeso, Inc.: Akeso Announces Completion of Patient Enrollment in Phase III Clinical Trial for Ivonescimab as First-Line Treatment for Biliary Tract Cancer Compared to PD-L1 Therapy225HONG KONG, Sept. 2, 2025 /PRNewswire/ -- Akeso (9926.HK) has recently announced the completion of patient enrollment in its Phase III, multicenter, randomized...
► Artikel lesen
01.09.HSBC initiates Akeso stock with Buy rating on strong 1H25 results9
28.08.AKESO Once Plummets 7.5% on ~5% Discounted Shr Placement & Shareholder Sell-Down2
28.08.AKESO (09926): PLACING OF NEW SHARES UNDER GENERAL MANDATE AND PLACING OF EXISTING SHARES1
27.08.Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst7
27.08.Akeso shares surge as cancer drug achieves key milestone in China trial8
27.08.AKESO Opens 4.7% Higher; 1H Rev. Soars ~38%, Loss Widens5
Weiter >>
90 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1